

## Supporting information

for

### **Determination of vitamin D metabolites in various biological samples through an improved chemical derivatization assisted liquid chromatography-tandem mass spectrometry**

Qin-Feng Zhang <sup>ac</sup>, Hua-Ming Xiao <sup>a</sup>, Na An <sup>a</sup>, Quan-Fei Zhu <sup>\*b</sup>, Yu-Qi Feng <sup>\*ab</sup>

<sup>a</sup> *Department of Chemistry, Wuhan University, Wuhan 430072, PR China*

<sup>b</sup> *School of Public Health, Wuhan University, Wuhan 430071, PR China*

<sup>c</sup> *Hubei Geological Research Laboratory, Wuhan 430034, PR China*


\* Corresponding authors:

Quan-Fei Zhu. *E-mail address:* qf\_zhu@whu.edu.cn

Yu-Qi Feng. *E-mail address:* yqfeng@whu.edu.cn

The Supporting information includes following items:

Page S3	Fig. S1. The chemical structures of 7 VDs.
Page S4	Fig. S2. Stability of PTAD derivatives under 4 °C for 24 h.
Page S5	Fig. S3. MS/MS spectra of 7 VDs after PTAD derivatization.
Page S6	Table S1. MRM transition parameters of PTAD-derived VDs.
Page S7	Table S2. PTAD derivatization efficiency of 7 VDs in standard solution and three biological samples.
Page S8	Table S3. LOD, LOQ, linear dynamic range and regression curve of PTAD-derived VDs.
Page S9	Table S4. Precisions (intra- and inter-day) and recoveries.
Page S10	Table S5. Extraction efficiency and matrix effect.



**Fig. S1.** The chemical structures of 7 VD metabolites.





Fig. S2. Stability of 7 PTAD derivatives under 4 °C for 24 h.



**Fig. S3.** MS/MS spectra of 7 VD metabolites after PTAD derivatization. (a) VD<sub>2</sub>. (b) VD<sub>2</sub>. (c) DHVD<sub>2</sub>. (d) VD<sub>3</sub>. (e) HVD<sub>3</sub>. (f) DHVD<sub>3</sub>. (g) THVD<sub>3</sub>.

**Table S1.** MRM transition parameters of PTAD-derived VDs.

Analytes	Scan mode	Precursor ion ( <i>m/z</i> )	Product ion ( <i>m/z</i> )	Dwell Time (msec)	Q1 Pre Bias (V)	CE	Q3 Pre Bias (V)
VD <sub>2</sub>	+	572.3	<b>298.1</b>	50	-26	19	-30
			280.1	50	-26	29	-29
HVD <sub>2</sub>	+	570.3	<b>298.1</b>	50	-28	18	-30
			280.1	50	-26	30	-29
DHVD <sub>2</sub>	+	586.3	<b>314.1</b>	50	-26	21	-14
			296.1	50	-26	31	-30
VD <sub>3</sub>	+	560.3	<b>298.1</b>	50	-20	18	-20
			280.1	50	-26	30	-29
HVD <sub>3</sub>	+	558.3	<b>298.1</b>	50	-26	16	-20
			280.1	50	-26	28	-29
DHVD <sub>3</sub>	+	574.3	<b>314.1</b>	50	-20	18	-14
			296.1	50	-20	28	-19
THVD <sub>3</sub>	+	590.3	<b>314.1</b>	50	-28	23	-14
			296.1	50	-26	30	-30
VD <sub>2</sub> -d <sub>3</sub>	+	575.3	<b>301.1</b>	50	-20	21	-20
			283.1	50	-20	30	-30
DHVD <sub>3</sub> -d <sub>3</sub>	+	577.3	<b>317.1</b>	50	-20	22	-22
			299.1	50	-20	30	-20

The product ions in **bold** were used for quantification.

**Table S2.** PTAD derivatization efficiency of 7 VDs in standard solution, human serum, mouse liver, and cell extract.

<b>Analytes</b>	<b>Derivatization efficiency (%)</b>			
	<b>Standard solution</b>	<b>Serum extract</b>	<b>Liver extract</b>	<b>Cell extract</b>
VD <sub>3</sub>	99.7	98.1	92.1	88.9
VD <sub>2</sub>	99.0	110.8	72.3	95.6
HVD <sub>3</sub>	97.0	94.4	85.6	103.1
HVD <sub>2</sub>	99.7	86.3	75.3	88.6
DHVD <sub>3</sub>	92.5	79.6	111.2	90.3
DHVD <sub>2</sub>	97.0	103.1	94.4	84.7
THVD <sub>3</sub>	96.0	86.0	70.6	106.8

**Table S3.** LODs, LOQs, linear dynamic range and regression curve of PTAD-derived VDs.

Analytes	LODs (pg mL <sup>-1</sup> )	LOQs (pg mL <sup>-1</sup> )	Linear dynamic range (ng mL <sup>-1</sup> )	Regression line		
				Slope	Intercept	R <sup>2</sup>
VD <sub>3</sub>	3	10	0.05-50	0.23	0.10	0.9963
VD <sub>2</sub>	3	10	0.05-50	0.23	0.19	0.9936
HVD <sub>3</sub>	10	30	0.10-100	0.25	0.22	0.9962
HVD <sub>2</sub>	7	20	0.10-100	0.29	0.33	0.9968
DHVD <sub>3</sub>	13	40	0.10-100	0.31	0.35	0.9943
DHVD <sub>2</sub>	10	30	0.10-100	0.07	0.08	0.9933
THVD <sub>3</sub>	20	70	0.20-200	0.12	0.23	0.9966



**Table S4.** Precisions (intra- and inter-day) and recoveries for analysis of PTAD-derived VDs in three different concentrations (0.2, 2, and 50 ng mL<sup>-1</sup>).

Analytes	Intra-day precision (RSD, %; n = 5)			Inter-day precision (RSD, %; n = 3)			Recoveries (%; n = 3)		
	Low	Medium	High	Low	Medium	High	Low	Medium	High
VD <sub>3</sub>	14.2	7.6	5.8	9.7	7.3	6.1	79.1	89.8	97.6
VD <sub>2</sub>	12.1	6.3	3.4	14.5	6.8	5.8	87.9	98.4	102.3
HVD <sub>3</sub>	7.5	7.5	4.4	16.5	9.2	7.9	78.8	93.6	110.2
HVD <sub>2</sub>	9.7	6.1	3.7	15.6	8.4	5.5	108.4	89.2	92.1
DHVD <sub>3</sub>	15.5	5.7	3.5	10.4	8.7	6.2	92.5	85.6	96.8
DHVD <sub>2</sub>	7.4	7.3	3.2	14.9	9.7	5.7	84.7	103.1	102.2
THVD <sub>3</sub>	8.4	8.3	4.5	9.2	7.6	7.1	85.7	100.5	100.2

**Table S5.** Extraction efficiency and matrix effect for VDs from human serum, mouse liver, and MLF cell using our established method.

Analytes	Extraction efficiency (%)			Matrix effect (%)		
	Serum	Liver	Cell	Serum	Liver	Cell
VD <sub>3</sub>	81.3	87.5	88.4	81.3	108.2	91.3
VD <sub>2</sub>	86.9	86.0	86.3	86.9	75.2	106.9
HVD <sub>3</sub>	100.3	70.4	85.9	100.3	98.6	103.8
HVD <sub>2</sub>	75.5	75.9	86.2	75.5	82.6	75.7
DHVD <sub>3</sub>	79.0	80.8	87.2	79.0	79.9	119.1
DHVD <sub>2</sub>	98.8	92.8	104.9	98.8	77.8	98.8
THVD <sub>3</sub>	83.9	89.6	83.5	73.9	83.0	83.9